Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY

Journal of Research in Pharmacy Practice Pub Date : 2022-07-01 DOI:10.4103/jrpp.jrpp_86_21

Tayebeh Mohammadi, Jafar Nasiri, Mohammad Reza Ghazavi, Omid Yaghini, Neda Hoseini

{"title":"Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial.","authors":"Tayebeh Mohammadi, Jafar Nasiri, Mohammad Reza Ghazavi, Omid Yaghini, Neda Hoseini","doi":"10.4103/jrpp.jrpp_86_21","DOIUrl":null,"url":null,"abstract":"Objective: Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.Methods: This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.Findings: The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.Conclusion: LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"109-115"},"PeriodicalIF":0.8000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/ef/JRPP-11-109.PMC10252575.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_86_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.

Methods: This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.

Findings: The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.

Conclusion: LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.

Abstract Image

查看原文本刊更多论文

拉科沙胺加药治疗儿童和青少年难治性局灶性癫痫的疗效:一项开放标签临床试验。

目的:癫痫是一种影响0.5%-1%儿童的慢性神经系统疾病。30%-40%的患者对目前的抗癫痫药物有耐药性。拉科沙胺(LCM)在儿童和青少年中似乎是有效、安全且耐受性良好的。本研究旨在评估LCM是否可以作为难治性局灶性癫痫患儿的有效补充治疗。方法:本研究于2020年4月至2021年4月在伊朗伊斯法罕伊玛目侯赛因儿童医院进行。我们纳入了44名6个月至16岁的难治性局灶性癫痫患儿(基于国际抗癫痫联盟的标准)。LCM分次给药，每天2 mg/kg，每周增加2 mg/kg。第一次随访时间为6周后，所有患者均达到治疗剂量。结果:患者平均年龄89.9个月。72.5%的儿童发生局灶性运动癫痫。治疗前后癫痫发作频率和持续时间的百分比变化评估显示，治疗后癫痫发作频率减少53.22%，癫痫发作持续时间减少43.72%。我们的研究组对LCM耐受性良好，几乎没有副作用。头痛、头晕和恶心是常见的副作用。与其他研究一致，没有任何可疑的危险因素可以预测对LCM治疗的反应。结论:LCM似乎是一种有效、安全且耐受性良好的药物，用于治疗无法控制的耐药局灶性癫痫患儿。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

21 weeks

期刊介绍： The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.